1 |
US Food and Drug Administration (1992). Guidance on Statistical procedures for Bioequivalence using a standard two-treatment crossover design, Rockville, MD.
|
2 |
US Food and Drug Administration (2001). Statistical Approaches to Establishing Bioequivalence, Rockville, MD.
|
3 |
Anderson, S. and Hauck, W. W. (1990). Consideration of individual bioequivalence, Journal of Pharmacokinetics and Pharmacodynamics, 18, 259-273.
DOI
|
4 |
Hyslop, T., Hsuan, F. and Holder, D. J. (2000). A small sample confidence interval approach to assess individual bioequivalence, Statistics in Medicine, 19, 2885-2897.
DOI
ScienceOn
|
5 |
Chow, S. C., Shao, J. and Wang, H. (2002). Individual bioequivalence testing under 2 3 designs, Statistics in Medicine, 21, 629-648.
DOI
ScienceOn
|
6 |
Esinhart, J. D. and Chinchilli, V. M. (1994). Extension to the use of tolerance intervals for the assessment of individual bioequivalence, Journal of Biopharmaceutical Statistics, 4, 39-52.
DOI
ScienceOn
|
7 |
Howe, W. G. (1974). Approximate confidence limits on the mean of X + Y where X and Y are two tabled independent random variables, Journal of the American Statistical Association, 69, 789-794.
DOI
|
8 |
Sheiner, L. B. (1992). Bioequivalence revisited, Statistics in Medicine, 11, 1777-1788.
DOI
ScienceOn
|
9 |
Schall, R. and Luus, H. G. (1993). On population and individual bioequivalence, Statistics in Medicine, 12, 1109-1124.
DOI
ScienceOn
|